Allarity Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
Allarity Therapeutics, Inc. (ALLR), a Delaware corporation, filed this Current Report on Form 8-K on August 23, 2022. The Company is an emerging growth company with its principal executive offices in Cambridge, MA. The report addresses a regulatory compliance issue regarding the listing of its common stock on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing is a current report regarding a listing notice and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Events
- Nasdaq Delisting Notice: On August 23, 2022, the Company received a notice from Nasdaq stating it is no longer in compliance with Listing Rule 5250(c)(1) due to the failure to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2022.
- Compliance Deadline: The Company has 60 calendar days (until October 24, 2022) to regain compliance by filing the Form 10-Q or submitting a compliance plan.
- Current Listing Status: The notice has no immediate effect on the listing of the Company's common stock on Nasdaq.
Outlook, Management Commentary, and Risks
Management intends to file the overdue Form 10-Q as soon as practicable. If the Company cannot file by October 24, 2022, it plans to submit a compliance plan to Nasdaq. If accepted, Nasdaq may grant an additional 180 days (until February 20, 2023) to regain compliance. If the plan is rejected, the Company retains the right to appeal to a Nasdaq Hearings Panel. The primary risk is potential delisting if compliance is not achieved within the specified timelines.
Key Facts for Investor Verification
- Verify the filing status of the Form 10-Q for the quarter ended June 30, 2022.
- Monitor the October 24, 2022 deadline for filing the report or submitting a compliance plan.
- Check for any subsequent announcements regarding the acceptance of a compliance plan or an appeal to the Nasdaq Hearings Panel.
- Confirm the continued trading status of ALLR on Nasdaq following the notice.